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www.cdatm.orgAbstractObjective: This study explores the correlation between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) and coronary
heart disease (CHD) by comparing the level of plasma Lp-PLA2 in the plasma of patients with different types of CHD.
Methods: Blood samples were collected from 56 patients diagnosed with CHD by the Department of Cardiology of the First
People's Hospital of Foshan and 34 healthy subjects from February 2013 to January 2014.Wemeasured the concentration of plasma
Lp-PLA2 and determined the levels of total cholesterol (Tch), triglyceride (TG), apolipoprotein A1 (Apo-A1), apolipoprotein B
(Apo-B), high density lipoprotein-cholesterol (HDL-c), low density lipoprotein-cholesterol (LDL-c), lipoprotein a (Lp(a)), glucose
(Glu), and high-sensitivity C-reactive protein (hs-CRP). The concentration of plasma Lp-PLA2 in the healthy control group and
each subgroup of CHD patients were compared and analyzed for correlations of plasma Lp-PLA2 between the patients in different
CHD subgroups and several laboratory indicators.
Results: The concentration of plasma Lp-PLA2 in each subgroup of CHD was significantly higher than in the control group
(P < 0.05). The concentration of Lp-PLA2 in the unstable angina pectoris (UAP) group and acute myocardial infarction (AMI)
group were significantly higher than in the stable angina pectoris (SAP) group (P< 0.05), and the concentration of plasma Lp-PLA2
in the AMI group was significantly higher than in the UAP group (P < 0.05). The concentration of plasma Lp-PLA2 in the CHD
group merely showed a positive correlation (r ¼ 0.493, P < 0.05) with the hs-CRP group, but the levels of Tch, TG, Apo-A1,
Apo-B, HDL-c, LDL-c, Lp(a) and Glu did not.
Conclusions: The concentration of plasma Lp-PLA2 in patients with CHD was higher than that in the control group. The
concentration of plasma Lp-PLA2 in the subgroups of CHD patients varied greatly from each other. The inflammatory response
of atherosclerosis might be resulted from the synergy of plasma Lp-PLA2 and hs-CRP.* Corresponding author.
E-mail address: 289124834@qq.com (X.-L. Yang).
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of the most common cardiovascular diseases and
severely endangers human health. In developed coun-
try, CHD is one of the major diseases that threaten
human health. Recent years the morbidity of CHD in
China is increasing, the patients are getting younger.1
Therefore, it is important and necessary to study
factors correlated with CHD.
The mechanism of CHD involves several factors,
among which one important pathological factor is
atherosclerosis (AS). Inflammatory mediators are
involved in the formation, development and even the
final rupture of atheromatous plaque and the inflam-
matory response plays an important role in the occur-
rence and development of atheromatous plaque.2 A
recent study found that Lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) served as a new inflammation
marker associated with CHD, it may directly partici-
pate in AS, and it is able to independently forecast
coronary events.3,4 A large number of clinical studies
abroad found that Lp-PLA2 had various close associ-
ations with CHD.5e7
We aim to discuss the relationship of Lp-PLA2 with
CHD as well as its correlation with blood lipid levels
and high-sensitivity C-reactive protein (hs-CRP) by
comparing the levels of Lp-PLA2 in CHD patients and
a healthy control group.
Materials and methods
Research subjects
Blood were drawn from 56 patients who were
hospitalized and had a coronary angiography (CAG) in
the Department of Cardiology of the First People's
Hospital of Foshan from February 2013 to January
2014. There are 37 men (66.07%) and 19 women
(33.93%), age 45e85 years, with an average age of
62.85 ± 12.42 years. Patients include 10 cases of stable
angina pectoris （SAP）, 11 of unstable angina pec-
toris (UAP), and 45 with acute myocardial infarction
(AMI). The control group was made up by 34 healthy
individuals aging 42e88 years, with an average age of
62.85 ± 12.42 years, selected from the Physical Ex-
amination Center of the First People's Hospital ofFoshan during the corresponding period. The following
conditions were excluded; cardiomyopathy, valvular
heart disease, severe hepatic and renal dysfunction,
malignant tumor, acute infection, long-term medica-
tion with lipid-lowering drugs, taking statins drugs or
aspirin before drawing blood.8,9
Methods
Specimen collection
Venous blood samples of all subjects were
collected from the elbow after overnight fasting after
hospitalization and samples were immediately sent
for analysis. For biochemical test blood were injected
into separation gel tubes while for Lp-PLA2 blood
was drawn into an EDTA-Na2 anticoagulant tube.
General clinical data were recorded, such as gender
and age.
Testing method
The quantitative determination of Lp-PLA2 was
measured by enzyme-linked immunosorbent assay
(ELISA), while the seven indicators of blood lipids and
blood glucose were determined with an automatic
biochemical analyzer (Olympus AU5421), hs-CRP was
determined with a BN II Immune Turbidimetry.
Statistics process
SPSS17.0 statistical software (SPSS Inc., IL, USA)
was applied for data analysis. Measurement data are
represented by mean ± standard deviation (SD), sam-
ples were compared between subgroups by t-tests and
the analysis of variance. Correlation analyses are
shown by Pearson linear correlation. P < 0.05 was
considered statistically significant.
Results
Comparison of clinical data
Comparing each CHD subgroup with the control
group for age, gender ratio, high blood pressure, and
smoking, there was no statistically significant differ-
ence, P > 0.05 (Table 1).
Table 1
Comparison of clinical data among subgroups.
Factor Control group (n ¼ 34) SAP group (n ¼ 10) UAP group (n ¼ 10) AMI group (n ¼ 36)
Age (years) 62.85 ± 12.42 73.00 ± 8.86 65.60 ± 10.70 66.31 ± 12.15
Male (n, %) 20 (58.82) 6 (6/10) 6 (6/10) 25 (69.44)
Hypertension (n, %) 15 (44.12) 6 (6/10) 4 (4/10) 16 (44.44)
Smoking (n, %) 8 (23.53) 5 (5/10) 5 (5/10) 10 (27.78)
SAP: stable angina pectoris; UAP: unstable angina pectoris; AMI: acute myocardial infarction.
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subgroups and other laboratory indexes
The concentration of plasma Lp-PLA2 in each CHD
subgroup was significantly higher than that in the
control group (P < 0.05). The concentration of
Lp-PLA2 in UAP group and AMI group were higher
than SAP group respectively (P < 0.05); meanwhile,
there was difference between AMI group and UAP
group (P < 0.05). The level of hs-CRP of AMI group
was apparently higher than that in the control group,
SAP group as well as USP group (P < 0.05). The level
of Lp(a) in each subgroup of CHD was higher than that
in the control group, among which, there was statistical
significance (P < 0.05) between AMI group and the
control group while no statistical significance between
SAP group as well as UAP group and the control
group. Regarding to the level of Glu, each CHD sub-
group was higher than control group, and the statistical
significance (P < 0.05) was only shared between AMI
group and the control group while there was no sta-
tistical significance shown between SAP group as well
as UAP group and the control group. For the levels of
Tch, TG, Apo-A1, Apo-B, HDL-c, LDL-c, although
there was difference between each subgroup of CHD
and the control group, the difference failed to show
statistical significance (P > 0.05) (Table 2).Table 2
Comparison of laboratory indexes among groups.
Index Control group (n ¼ 34) SAP group (n
Lp-PLA2 (ng/ml) 32.65 ± 37.87 145.00 ± 40.6
Tch (mmol/L) 4.71 ± 1.01 4.62 ± 0.98
TG (mmol/L) 1.55 ± 0.70 1.26 ± 0.45
Apo-A1 (g/L) 1.32 ± 0.30 1.22 ± 0.20
Apo-B (g/L) 0.98 ± 0.31 0.98 ± 0.27
HDL-c (mmol/L) 1.26 ± 0.34 1.05 ± 0.15
LDL-c (mmol/L) 3.11 ± 0.97 3.01 ± 0.82
Lp(a) (mg/L) 207.18 ± 182.67 370.9 ± 291
Glu (mmol/L) 6.69 ± 3.03 7.62 ± 3.39
hs-CRP (mg/L) 4.41 ± 3.09 7.22 ± 4.80
* compared with the control group and P < 0.05; # compared with SAP gro
SAP: stable angina pectoris; UAP: unstable angina pectoris; AMI: acute m
pholipase A2; Tch: total cholesterol; TG: triglyceride; Apo-A1: apolipopro
cholesterol; LDL-c: low density lipoprotein-cholesterol; LP(a): lipoproteinThe correlation between concentrations of Plasma
Lp-PLA2 and other laboratory indexes
With bi-variate linear analysis, it can be found that
among the whole population of this study, the con-
centration of plasma Lp-PLA2 was positively corre-
lated with the levels of Glu and hs-CRP (r ¼ 0.249,
P < 0.05; r ¼ 0.616, P < 0.05), while no correlation
with levels of Tch, TG, Apo-A1, Apo-B, HDL-c, LDL-
c,LP(a). In CHD group, the concentration of plasma
Lp-PLA2 only had positive correlation with hs-CRP
(r ¼ 0.493, P < 0.05), and no correlation with levels
of other indexes, like Tch, TG, Apo-A1, Apo-B, HDL-
c, LDL-c, LP(a), Glu, was found. In the control group,
the concentration of plasma Lp-PLA2 had positive
correlation with TG and Glu (r ¼ 0.410, P < 0.05;
r ¼ 0.397, P < 0.05) (Table 3).
Discussion
At present, CHD is one of severe threat to public
health and its morbidity, disability rate and mortality
are rising year by year. Though many search on
the pathogenesis of CHD, there is no recognized
theory yet. Directly related to the occurrence of
CHD, atherosclerosis is a disease closely related to
inflammation, a dynamic pathologic change when¼ 10) UAP group (n ¼ 10) AMI group (n ¼ 36)
1* 195.55 ± 87.80*# 453.40 ± 272.45*#@
4.84 ± 1.01 4.98 ± 1.25
1.61 ± 0.82 1.56 ± 0.56
1.29 ± 0.24 1.35 ± 0.30
0.98 ± 0.35 1.06 ± 0.35
1.12 ± 0.66 1.10 ± 0.36
3.07 ± 0.94 3.08 ± 1.16
.09 375.40 ± 230.81 383.94 ± 328.77*
7.72 ± 2.60 8.87 ± 3.44*
9.22 ± 5.11 39.16 ± 25.77*#@
up and P < 0.05; @ compared with UAP group and P < 0.05.
yocardial infarction; Lp-PLA2: plasma lipoprotein-associated phos-
tein A1; Apo-B: apolipoprotein B; HDL-c: high density lipoprotein-
a; Glu: glucose; Hs-CRP: high-sensitivity C-reactive protein.
Table 3
The Pearson correlation coefficient of Lp-PLA2 and other indexes.
Indices All subjects (n ¼ 90) Control group (n ¼ 34) CHD group (n ¼ 56)
r P r P r P
Tch 0.019 0.860 0.016 0.930 0.101 0.461
TG 0.022 0.838 0.410 <0.05 0.023 0.868
Apo-A1 0.036 0.734 0.151 0.394 0.048 0.724
Apo-B 0.002 0.985 0.141 0.426 0.090 0.511
HDL-c 0.05 0.642 0.219 0.212 0.138 0.310
LDL-c 0.093 0.385 0.307 0.078 0.146 0.282
LP(a) 0.056 0.602 0.038 0.831 0.191 0.159
Glu 0.249 <0.05 0.398 <0.05 0.124 0.364
hs-CRP 0.616 <0.05 0.206 0.427 0.493 <0.05
Tch: total cholesterol; TG: triglyceride; Apo-A1: apolipoprotein A1; Apo-B: apolipoprotein B;HDL-c: high density lipoprotein-cholesterol; LDL-c:
low density lipoprotein-cholesterol; LP(a): lipoprotein a; Glu: glucose; hs-CRP: high-sensitivity C-reactive protein; CHD coronary heart disease.
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inflammatory response. Inflammatory cytokines play
an important role in the occurrence, development and
rupture of AS plaque.10,11
Lp-PLA2, also called platelet-activating factor
acetylhydrolase (PAF-AH), is an enzyme which can
catalyze the hydrolysis of lipoprotein and glyceryl
phosphatide second acyl ester bond in the cell mem-
brane, producing non-esterified fatty acid and lyso-
phospholipase. In blood circulation, Lp-PLA2 is
mainly produced and secreted by mature macrophage
and lymphocyte, in which platelet activating factor can
promote the secretion.12
In the blood circulation, Lp-PLA2 is combined with
lipoprotein particle, among which 80% was combined
with LDL, 15%~20% with HDL and the rest with very
low density lipoprotein (VLDL).13 PAF can promote
the gather of platelet, the chemotaxis of neutrophils
and monocyte, the release of inflammatory mediator
like leukotrienes, the formation of thrombus and
inflammatory response. A latest research found that
Lp-PLA2 can hydrolyze the proinflammatory cyto-
kines PAF into the inactive lyso-PAF, which can reduce
the occurrence of inflammation and thrombus, anti-
inflammatory and antiatherosclerotic.14 On the other
hand, Lp-PLA2 also can hydrolyze oxydic lecithin of
the blood vessel intima, producing Lysophosphati-
dylcholine (lyso-PC) and oxidized free fatty acids
(ox-FFA), and these two products are proinflammatory
mediator which can stimulate and produce adhesion
molecule and cytokines, and further the gathering
movement of monocyte from lumen to intima.
Macrophage is derived from the gather of monocyte in
intima and then turns into foam cell by phagocytosing
oxidised low density lipoprotein (ox-LDL) and finally
gather to form AS plaque which can release cytokines
and protease, degradate smooth muscle cell andcollagen matrix of fibrous cap, leading to the fragility
and rupture of plaque, further resulting in the forma-
tion of thrombus and occurrence of cardiovascular
events.15,16 The role that LP-PLA2 plays in the process
of AS is still controversial, but more and more
evidence indicates that LP-PLA2 can facilitate AS.
This study found that after the adjustment for age,
gender, the concentration of plasma Lp-PLA2 in the
subgroups of CHD varied greatly from the control
group as well as from each other: great difference
appeared between SAP group and either UAP group or
AMI group; so did between AMI group and UAP
group. With the comparison, it can be found that
Lp-PLA2 may play a stimulative role in AS, related to
the occurrence and development of CHD and its clin-
ical type, which was valuable for the judgment of
CHD. The concentration of plasma Lp-PLA2 in AMI
group was higher than that in UAP group, which may
result from that for patients with AMI, the rupture of
AS plaque and formation of thrombus led to angiem-
phraxis and the formation of atheromatous plaque
caused by inflammatory response was stronger in AMI
group than in UAP group.
The study showed the increasement of hs-CRP was
associated with the instability (severity) of athero-
sclerotic plaque, but there was no statistically signifi-
cant; while the concentration of Lp-PLA2 rose with the
increase of the instability (severity) of atherosclerotic
plaque, and there was statistically significant. Mean-
while, in the analysis on the correlation between Lp-
PLA2 and the inflammation marker of hs-CRP, it was
found that the concentration of Lp-PLA2 was slightly
related to the level of hs-CRP. It meant that Lp-PLA2
may, associate with hs-CRP inflammatory factor, take
part in the inflammatory response of AS. The reason
may be that Lp-PLA2 shared different physiopatho-
logic mechanism with hs-CRP in the process of AS, or
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different roles in AS: hs-CRP maybe is a product in the
acute nonspecific inflammatory response while Lp-
PLA2 may play a more specific role in
cardiovascular inflammation.
Lp-PLA2 had no correlation with other laboratory
index, which can be learned from their correlation
analysis. This result was different from some other
domestic research, which may be accounted for the
difference of ares, group characteristics and the num-
ber of cases involved in this study.
In conclusion, this research investigated the changes
of concentration of Lp-PLA2 in different group of
CHD patients and its correlation with blood lipid and
hs-CRP. Though there is no recognized theory about
the role which Lp-PLA2 plays in the process of AS,
this study confirmed that Lp-PLA2 can promote AS
and had close correlation with CHD. Moreover, it may
predict the occurrence of CHD events. It remains to be
confirmed by further studies on the exact impact and
mechanism of Lp-PLA2, which shows importantly
clinical significance for the prevention and treatment of
AS events. It presents more predictive value for the fact
that traditional risk factors cannot be identified on
those people at risk. Therefore, Lp-PLA2 may be a
potential target for CHD diagnosis.
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